

STJ

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q81147

Nobukazu ONISHI, et al.

Appln. No.: 10/826,303

Group Art Unit: 1615

Confirmation No.: 9815

Examiner: Susan T. TRAN

Filed: April 19, 2004

For: AGENT AND FOOD FOR INHIBITING IGE ANTIBODY

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of the listed document is submitted herewith.

KAMOYOSHI, Y. et al., "Safety and Effects of Pulverized Konjac Glucomannan in Patients with Atopic Dermatitis and Allergic Rhinitis", *Japanese Pharmacology & Therapeutics*, Jan. 20, 2006, pages 97-102, vol. 34, no. 1.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of

INFORMATION DISCLOSURE STATEMENT

U.S. Application No.: 10/826,303

Attorney Docket No.: Q81147

Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and the fee of \$180.00 under 37 C.F.R. § 1.17(p) is to charge Deposit Account No. 19-4880.

A partial English translation and an English language Abstract of foreign language document are being submitted herewith, and therefore no concise explanation for such foreign language documents is required.

The submission of the listed document is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Kim E. Choate  
Registration No. 57,102

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**


CUSTOMER NUMBER

Date: December 22, 2006

Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Complete if Known

Application Number	10/826,303
Confirmation Number	9815
Filing Date	April 19, 2004
First Named Inventor	Nobukazu ONISHI
Art Unit	1615
Examiner Name	Susan T. TRAN
Attorney Docket Number	Q81147

Sheet

1

of

1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		KAMOYOSHI, Y. et al., Safety and Effects of Pulverized Konjac Glucomannan in Patients with Atopic Dermatitis and Allergic Rhinitis, Jpn Pharmacol Ther., Jan. 20, 2006, 97-102, vol. 34, no. 1, JAPAN.	Yes

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.